NEW YORK (AP) — Wall Street is holding near its record heights on Monday, ahead of a week likely to be dominated by updates ...

Viking Therapeutics' weight-loss pill trial results underwhelmed, causing a sharp decline in shares. Meanwhile, Novo Nordisk's liver disease approval for Wegovy uplifted its stock. European corporate ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Novo Nordisk (NYSE: NVO) stock is up 2.2% through 10:30 a.m. ET on Viking's bad news. Where to invest $1,000 right now? Our ...

Recent developments in weight-loss treatments have impacted the market significantly. Viking Therapeutics' new pill showed ...

Canada has approved Novo Nordisk's diabetes drug, Ozempic, to cut chronic kidney disease progression and reduce the risk of ...

World shares were mixed on Tuesday after Wall Street held near its records, with traders awaiting fresh cues about interest ...

Wall Street held near its record heights on Monday, ahead of a week likely to be dominated by updates from the head of the ...